Evidence map›Paper›PMID 15240271›Full record

ArticleApplied and environmental microbiology2004

Relationship between gyrA mutations and quinolone resistance in Flavobacterium psychrophilum isolates.

Shotaro Izumi, Futoshi Aranishi

Open access · greenAbstract read
In one paragraph

Article in Applied and environmental microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Tenacibaculosis caused byFrontiers in cellular and infection microbiology · 2022
    Review
  5. Phage-Mediated Control ofFrontiers in microbiology · 2021
    Article
  6. Article
  7. Antimicrobial Susceptibility ofFrontiers in microbiology · 2016
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Shotaro IzumiMolecular Biology Division, National Institute of Fisheries Science, Fukuura, Kanazawa, Yokohama, Kanagawa 236-8648, Japan. sizumi@affrc.go.jp or s-izumi@aa.e-mansion.com
Futoshi Aranishi
Japan Fisheries Research and Education Agency · JPUniversity of Miyazaki · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flavobacterium psychrophilum is the causative agent of the fish diseases called bacterial cold-water disease and rainbow trout fry syndrome. It has been reported that some isolates of F. psychrophilum are resistant to quinolones; however, the mechanism of this quinolone resistance has been unexplained. In this study, we examined the quinolone susceptibility patterns of 27 F. psychrophilum strains isolated in Japan and the United States. Out of 27 isolates, 14 were resistant to both nalidixic acid (NA) and oxolinic acid (OXA), and the others were susceptible to NA and OXA. When amino acid sequences deduced from gyrA nucleotide sequences of all isolates tested were analyzed, two amino acid substitutions (a threonine residue replaced by an alanine or isoleucine residue in position 83 of GyrA [Escherichia coli numbering] and an aspartic acid residue replaced by a tyrosine residue in position 87) were observed in the 14 quinolone-resistant isolates. These results strongly suggest that, as in other gram-negative bacteria, DNA gyrase is an important target for quinolones in F. psychrophilum.

Indexed as

MutationAmino Acid SequenceDNA GyraseDrug Resistance, BacterialFlavobacteriumMicrobial Sensitivity TestsMolecular Sequence DataNalidixic AcidOxolinic AcidPolymerase Chain ReactionDNA GyraseNalidixic AcidOxolinic Acid

Identifiers

PMID15240271
PMCPMC444768
OpenAlexW2120139933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.